SEC Form 4 · accession 0001140361-16-067949
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — EVP, Chief Medical Officer
Period of report
May 26, 2016
Accepted (ET)
May 31, 2016 · 6:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 26, 2016 | M | 15,000 | $26.49 | A | 130,914 | D | |
| Common StockF1 | May 26, 2016 | S | 10,000 | $88.04 | D | 120,914 | D | |
| Common StockF2 | May 26, 2016 | S | 5,000 | $87.34 | D | 115,914 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock (Right to buy Common Stock)F3 | $26.49 | May 26, 2016 | M | 15,000 | D | Nov 12, 2011 | May 11, 2021 | Common Stock | 15,000 | 65,225 | D |
Explanation of responses
- F1All shares were sold at the same price
- F2The price in column 4 is a weighed average price. The price actually received ranged from $86.50 to $88.34. The reporting person will provide to the issuer, and security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.